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Background: Rapid diagnostic tests are commonly 
used by hospital laboratories in England to detect 
rotavirus (RV), and results are used to inform clinical 
management and support national surveillance of the 
infant rotavirus immunisation programme since 2013. 
In 2017, the Public Health England (PHE) national ref-
erence laboratory for enteric viruses observed that 
the presence of RV could not be confirmed by PCR in 
a proportion of RV-positive samples referred for con-
firmatory detection. Aim: We aimed to compare the 
positivity rate of detection methods used by hospital 
laboratories with the PHE confirmatory test rate.
Methods: Rotavirus specimens testing positive at local 
hospital laboratories were re-tested at the PHE national 
reference laboratory using a PCR test. Confirmatory 
results were compared to original results from the PHE 
laboratory information management system. Results: 
Hospital laboratories screened 70.1% (2,608/3,721) 
of RV samples using immunochromatographic assay 
(IC) or rapid tests, 15.5% (578/3,721) using enzyme 
immunoassays (EIA) and 14.4% (535/3,721) using 
PCR. Overall, 1,011/3,721 (27.2%) locally RV-positive 
samples referred to PHE in 2016 and 2017 failed RV 
detection using the PHE reference laboratory PCR test. 
Confirmation rates were 66.9% (1,746/2,608) for the IC 
tests, 87.4% (505/578) for the EIA and 86.4% (465/535) 
for the PCR assays. Seasonal confirmation rate dis-
crepancies were also evident for IC tests. Conclusions: 
This report highlights high false positive rates with 
the most commonly used RV screening tests and 
emphasises the importance of implementing verified 
confirmatory tests for RV detections. This has implica-
tions for clinical diagnosis and national surveillance.
Introduction
Rotavirus (RV) infection is a common cause of severe 
watery diarrhoea in young individuals around the world 
[1]. In healthy individuals, the disease is usually mild 
and self-limiting, with symptoms lasting between 3 
and 8 days. However, in very young or immunocompro-
mised patients, RV infection can cause more severe 
manifestations including fever, vomiting, abdominal 
pain and dehydration. There is no specific treatment 
for RV infection; oral rehydration and intravenous fluid 
supplementation can be administrated to prevent or 
treat severe dehydration.
Prior to routine RV vaccination in the United Kingdom 
(UK), the burden of RV disease was estimated to be 
750,000 diarrhoea episodes [2], and 14,300 diarrhoea-
related hospital admissions of children under the age 
of five [3] every year, representing a considerable 
healthcare cost. In 2013, a monovalent live-attenuated 
RV vaccine was introduced into the UK infant immuni-
sation programme as a two-dose schedule at 8 and 16 
weeks of age. The programme resulted in a 77% reduc-
tion of laboratory-reported RV infections [4,5], and a 
26% decrease in gastroenteritis-associated hospitali-
sation in young children [4,6]. It is estimated that the 
RV immunisation programme was associated with a 
GBP 12.5 million (EUR 13.7 million converted on 9 Sep 
2020) saving in RV-associated healthcare costs within 
a year of implementation [6].
RV episodes are typically seasonal with most cases 
occurring during the winter and spring months (January 
to April in the temperate northern hemisphere). 
Following the introduction of RV immunisation, sea-
sonal patterns have shifted, with shorter and more 
delayed periods of RV disease activity observed in 
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some countries such as the United States (US) and 
Belgium [7-9].
In England, National Health Service (NHS) hospital 
laboratories routinely test stool samples from patients 
with gastroenteritis for a number of viruses including 
RV in order to confirm the diagnosis and inform clinical 
management. A variety of detection methods are used 
by NHS hospital laboratories for RV screening [10], such 
as immunoassay-based methods (i.e. enzyme-linked 
immunosorbent assay and immunochromatographic) 
and molecular assay-based methods (i.e. reverse tran-
scription and PCR).
As part of national surveillance of the RV immunisa-
tion programme in England, NHS hospital laboratories 
are actively requested to submit all positive RV stool 
samples to the Public Health England (PHE) Virus 
Reference Department (VRD) Enteric Virus Unit (EVU) 
reference laboratory for confirmation and additional 
characterisation to support the molecular surveillance 
of circulating RV strains. In recent years, an increas-
ing number of positive RV samples submitted by NHS 
hospital laboratories failed molecular characterisation. 
Therefore, a confirmatory PCR detection test was 
implemented at the PHE reference laboratory for all RV 
samples received; this PCR test is performed before 
attempting molecular characterisation. The PHE refer-
ence laboratory confirmatory PCR detection test identi-
fied a considerable proportion of RV-negative samples, 
suggesting a high rate of false positive results at some 
local NHS hospital laboratories.
The aim of this study was to determine the propor-
tion of samples that tested positive for RV in local NHS 
hospital laboratories, were submitted to the PHE refer-
ence laboratory and were also positive using the PHE 
reference laboratory confirmatory PCR test. The study 
also aimed to compare the results of the PHE reference 
laboratory confirmatory PCR test with the results from 
the original RV testing method used by the NHS hospi-
tal laboratory. Variations in performance of the differ-
ent tests during and outside the RV season were also 
assessed as part of the analysis.
Table
Rotavirus referred positive samples and confirmation rates, England, 2016–2017 (n = 3,721)
Test
Samples Confirmed
SE
95% CI
n Use (%) n PPV (%) Lower Upper
RORT 1 34 0.9 5 14.7 6.2 6.2 31.1
RORT 2 187 5.0 166 88.8 2.3 83.4 92.6
RORT 3 1,165 31.3 774 66.4 1.4 63.7 69.1
RORT 4 117 3.1 69 59.0 4.6 49.8 67.5
RORT 5 6 0.2 2 33.3 21.1 7.2 76.3
RORT 6 26 0.7 9 34.6 9.5 18.8 54.7
RART 7 5 0.1 4 80.0 20 25.6 97.9
RART 8 111 3.0 101 91.0 2.7 84 95.1
RART 9 48 1.3 43 89.6 4.5 77.1 95.6
RART 10 56 1.5 44 78.6 5.5 65.8 87.5
RART 11 244 6.6 189 77.5 2.7 71.8 82.3
RART 12 130 3.5 98 75.4 3.8 67.2 82.1
RART 13 16 0.4 12 75.0 11.2 48.2 90.6
RART 14 14 0.4 12 85.7 9.7 55.9 96.6
RART 15 29 0.8 21 72.4 8.4 53.4 85.7
RART 16 115 3.1 65 56.5 4.6 47.3 65.3
RART 17 305 8.2 132 43.3 2.8 37.8 48.9
EIA Commercial 1 248 6.7 230 92.7 1.7 88.8 95.4
EIA Commercial 2 233 6.3 199 85.4 2.3 80.3 89.4
EIA Other 97 2.6 76 78.4 4.2 69 85.5
PCR Commercial 1 80 2.1 37 46.3 5.6 35.6 57.3
PCR Commercial 2 44 1.2 27 61.4 7.4 46.2 74.6
PCR Commercial 3 6 0.2 6 100.0 0 NA NA
PCR In-house 405 10.9 395 97.5 0.8 95.5 98.7
Total 3,721 100 2,716 73.0 NA NA NA
CI: confidence interval; EIA: enzyme immunoassay; NA: not applicable; PPV: positive predictive value; RART: rotavirus and adenovirus rapid 
test; RORT: rotavirus only rapid test; RV: rotavirus; SE: standard error.
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Methods
Data source
Samples received at the PHE reference laboratory from 
5 January 2016 to 28 December 2017 were included in 
the analysis. Data were extracted from the PHE refer-
ence laboratory information management system, 
which contains all the information provided in the labo-
ratory request form, along with the results of the PHE 
reference laboratory confirmatory PCR test. For sam-
ples where the RV screening method was not stated on 
the laboratory request form, the individual laboratories 
were contacted directly.
Segregation of tests and methodologies
Commercial rapid tests, enzyme immunoassays (EIA) 
and PCR tests were identified in this study. Of the sev-
enteen types of commercial rapid tests used, six tar-
geted RV only (RORT1 to RORT6) and 11 were designed 
for dual detection of  RV and  adenovirus (RART7 to 
RART17). For EIA, three subgroups were created: two 
commercially available kits (commercial EIA1 and com-
mercial EIA2) and one group including other commer-
cial or in-house tests (other EIAs). The PCR category 
was subdivided into four groups, including commercial 
(PCR1 to PCR3) and PCR assays developed in-house (in-
house PCRs).
Rotavirus detection–PHE reference laboratory 
confirmatory PCR test targeting VP6 gene
Patients’ stool samples received from referring labo-
ratories across England were tested using real-time 
PCR (PHE reference laboratory confirmatory PCR) to 
determine the presence of RV RNA (n = 3,729). Partial 
amplification of the VP6 gene was performed as pre-
viously described [11,12] with modifications. Briefly, 
nucleic acid was extracted from 200μl of 10% fae-
cal suspensions by automatic RNA extraction plat-
form (MP96, Roche, Almere, the Netherlands or 
Qiasymphony, Qiagen, Hilden, Germany). A reverse 
transcription step was carried out with random hex-
amers (Invitrogen) followed by PCR amplification using 
primers VP6-F: 5’-GAC GGV GCR ACT ACA TGG T-3’; VP6-
R: 5’-GTC CAA TTC ATN CCT GGT GG-3’; and probe VP6P: 
FAM5’-CCA CCR AAY ATG ACR CCA GCN GTA -3’ MGB. 
cDNA was initially heated at 50 °C for two minutes and 
95 °C for 2 min, followed by 35 PCR cycles at 95 °C for 15 
s and 60 °C for one minute. Mengovirus was used as an 
internal process control (added before the nucleic acid 
extraction step) and detected using primers MengoF: 
5’-GCG GGT CCT GCC GAA AGT-3’, MengoR5’-GAA GTA 
ACA TAT AGA CAG ACG CAC AC-3’ and probe: MengoP5’-
VIC-ATC ACA TTA CTG GCC GAA GC-MGB-3’.
The limit of detection of the PHE reference laboratory 
confirmatory PCR test was determined by 10-fold serial 
dilutions of in vitro transcribed single stranded RNA 
derived from simian rhesus rotavirus (RRV) segment 
S6 as template. Copy number was calculated using the 
formula:
copy number (molecules/µL) = [concentration (ng/
µL) × 6.022 × 1023  (molecules/mol)]/ [length of ampli-
con × 650 (g/mol) × 109 (ng/g)].
The limit of detection of 3.4 × 103  copies of target 
RNA was determined as the lowest copy number 
that produced positive results in duplicates for two 
independent tests.
Figure 1
Positive predictive values of (A) rapid tests vs EIA and PCR and (B) individual testing method for rotavirus infection, 
England, 2016–2017 (n = 3,721)
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Specific PCRs targeting NSP3 gene
A subset of 59 samples was identified for further test-
ing. Criteria for selection were based on: (i) samples 
with a positive result by rapid tests but negative by 
PHE reference laboratory confirmatory PCR; (ii) sam-
ples received in the current (at the time) RV season to 
mitigate sample degradation. A specific PCR targeting 
NSP3 gene was performed as described elsewhere 
[13]. Briefly, after the reverse transcription step with 
random primers, PCR was performed using primers 
NVP3-Fdeg, NVP3-R1 and probe NVP3-Probe. The reac-
tion mixture consisted of 1 × TaqMan Universal master 
mix (Invitrogen), 0.2  μM each primer, 0.15  μM probe 
and 0.05 μl ROX dye. Amplification conditions were two 
minutes at 50 °C and one minute at 95 °C, followed by 
45 cycles of 15 s at 95 °C and one minute at 60 °C.
Electron microscopy
Clinical material for electron microscopy was selected 
based on: (i) the rapid test method and positive result; 
(ii) PHE reference laboratory confirmatory PCR result; 
(iii) availability of material; (iv) most recent speci-
men to minimise sample degradation. Specimens (19 
samples) screened by RORT2 (n  =  4), RORT3 (n  =  5), 
RORT4 (n  =  5) or RART11 (n  =  5) were included. Two 
positive samples and at least two negatives for the 
PHE reference laboratory confirmatory PCR per rapid 
test group were tested. Detailed methods are provided 
in Supplementary Materials and methods.
Statistical analysis
Data analysis was performed by calendar year based 
on sample receipt date at the PHE reference labora-
tory. Statistical analysis was performed using MS 
Excel and Stata v14.1 software (StataCorp, Texas, US). 
Confirmation rates or positive predictive values (PPV), 
standard errors (SE) and 95% confidence intervals 
(95%  CI) were calculated for all methods. PPV is the 
probability that the individuals with a positive screen-
ing result will truly have the disease. To test if there 
were any significant differences (p < 0.001) in PPV 
between the different testing methodologies and indi-
vidual tests, chi-squared tests were performed.
Ethical statement
PHE has legal permission, provided by Regulation 3 
of The Health Service (Control of Patient Information) 
Regulations 2002 [14], to process patient confidential 
information for national surveillance of communicable 
diseases and includes PHE’s responsibility to monitor 
the safety and effectiveness of vaccines.
Results
Rotavirus confirmed-positive samples
During the two-year surveillance period, 3,729 RV sam-
ples that tested positive at local NHS hospital labora-
tories were received by PHE reference laboratory for 
confirmation and additional characterisation. Of those 
3,729 samples, 3,721 were included in this data analy-
sis based on the completeness of information required 
and the statistical value. Eight samples were excluded 
from this study because they did not meet the criteria: 
seven samples lacked information on the screening 
methodology used by the local NHS hospital laborato-
ries and one sample had been tested using a commer-
cial PCR test, putting it in a PCR4 category of n = 1.
All samples were subjected to the PHE reference labo-
ratory confirmatory PCR test targeting VP6 gene before 
Figure 2
Positive predictive values by month and (A) testing methods and (B) rotavirus only rapid test, for rotavirus infection and 
month, England, 2016–2017 (n = 3,721)
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attempting strain characterisation. The PHE reference 
laboratory confirmatory PCR test was positive in 73% 
(2,716/3,721) of referred samples (Table).
Use of primary screening tests
For the purpose of this analysis, local testing methods 
were grouped in three categories: immunochroma-
tography-based or rapid test, enzyme immunoassays 
(EIA) and PCR tests. Most samples (2,608/3,721, 
70.1%) had been tested with rapid tests locally, while 
15.5% (578/3,721) had been tested by EIA and 14.4% 
(535/3,721) by PCR.
RORT3 was the most commonly used test with 1,165 
(31.3%) samples followed by in-house PCRs (405 sam-
ples, 10.9%). RART17 (305, 8.2%), commercial EIA1 
(248, 6.7%), RART11 (244, 6.6%) and commercial EIA2 
(233, 6.3%) were less frequently used, while RORT5 (6, 
0.2%), RART7 (5, 0.1%), RART13 (16, 0.4%), RART14 (14, 
0.4%) and commercial PCR3 categories (6, 0.2%) were 
each represented with less than 20 samples (Table).
PHE reference laboratory confirmation rates 
and positive predictive value
Of the 2,608 specimens with a positive rapid test 
result, the PHE reference laboratory confirmatory PCR 
test was positive in 1,746 (66.9%) of cases. Analysis of 
the positive predictive value (PPV) by testing method 
showed a clear difference between the rapid tests 
when compared with the EIA and PCR methods (Figure 
1A). PPVs were significantly higher (p < 0.001) for PCR 
(86.8%) and EIA (87.4%) methods compared with the 
RORT (66.8%) and RART (67.1%) rapid test methods. 
PPVs for individual tests ranged from 14.7% (5/34) for 
RORT1 to 91% (101/111) for RART8 (Table and Figure 1B). 
RV RNA was detected in less than 50% of samples ini-
tially tested with RORT1, RORT5, RORT6 or RART17. For 
the most commonly used rapid test, RORT3 (n = 1,165 
specimens), RV RNA was confirmed in only 774 (66.4%) 
samples.
Within the EIA group, results were more consistent and 
less variable, with PHE reference laboratory confirma-
tion rates ranging from 78.4% (76/97) for the other EIAs 
group to 92.7% (230/248) and 85.4% (199/233) for the 
two commercial EIA tests (EIA1 and EIA2, respectively).
Of the commercial PCRs used by local NHS hospital 
laboratories, there was variable and suboptimal perfor-
mance overall, with PHE confirmation of 61.4% (27/44) 
for commercial PCR2 and 46.3% (37/80) for commercial 
PCR1. By contrast, 97.5% (395/405) of in-house PCR 
and six of six commercial PCR3 assays were confirmed 
as positive by the PHE reference laboratory PCR test.
Seasonal variation
In order to assess whether the seasonal nature of 
RV activity may impact on PPV of screening tests, an 
analysis of the performance by methodology was 
conducted across each month. The rate of samples 
confirmed positive showed inconsistent variation per 
month (Figure 2A  and Table S1). All methodologies 
showed a decrease in confirmation rates during low-
season months (July to November) with lowest PPV for 
PCR occurring in July (21/39, 53.8%, 95%  CI: 38.1%–
68.9), for EIA in October (6/15, 40%, 95%CI: 18.6%–
66.1) and for rapid tests in November (50/150, 33.3%, 
95% CI: 26.2%–41.3). The PPVs of the rapid tests were 
the lowest of all methodologies for both high (January 
to April) and low seasons.
Analysis of seasonal variation on confirmation rates for 
RORT3, the rapid test with the highest number of speci-
mens, showed a similar pattern but with greater varia-
tion (Figure 2B and Table S2). The greatest proportion 
of samples confirmed as positive was observed in 
February (114/123, 92.7%), with 89.6% (403/450) 
for the complete peak RV season (January to April). 
Outside the RV season, the confirmation rate was only 
21.4% (32/149) with the lowest percentage observed 
during September (1/15, 6.7%).
Detection of rotavirus NSP3 gene and electron 
microscopy
To further confirm our findings, selected samples were 
subjected to two additional detection assays. A subset 
of 59 specimens initially screened positive by rapid 
tests but negative by the PHE reference laboratory con-
firmatory PCR test, was tested by PCR amplification of 
the NSP3 gene. Only two samples (2/59, 3.4%) were 
positive indicating that 96.6% of the samples were true 
negatives. Cycle threshold (Ct) values for NSP3 tests 
for the two samples (Ct: 34.9 and 37.0) suggested the 
presence of RV at a very low genome content.
Electron microscopy (EM) was also performed on 19 
samples to visualise any viral particles. Eight samples 
found positive by both rapid test and PHE reference 
laboratory confirmatory PCR test were all confirmed 
as positive by virus particle visualisation (data not 
shown), while eleven specimens with a negative PHE 
reference laboratory confirmatory PCR test result also 
failed particle detection under EM (Table S3).
Discussion
Our results highlight the importance of validating 
screening results for RV diagnosis. The strong repro-
ducibility of the results for referred samples that were 
screened by in-house PCR tests supports this method-
ology for RV detection. However, only 10.9% (405/3,721) 
of the samples were screened using this methodology. 
The commercial PCR tests PCR1 and PCR2 performed 
less well in comparison to in-house PCRs (confirmation 
rate of 46.3% and 61.4% for PCR1 and PCR2, respec-
tively, compared with 97.5% for the in-house PCR). In 
addition, a greater proportion of PCR1 and PCR2 sam-
ples failed to be confirmed as positive at the PHE refer-
ence laboratory: 53.8% (43/80) of PCR1; 38.6% (17/44) 
of PCR2 and 2.5% (10/405) of in-house PCR samples 
failed. Commercial PCR detection kits are marketed as 
very specific and sensitive tests for RV detection but 
remarkably, the commercial PCR tests included in our 
analysis revealed a variable confirmation rate. It is 
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unclear why in-house PCR assays out-performed com-
mercial PCR assays. One possible explanation may be 
differences in assay validation, since the development 
of in-house assays could include more stringent local 
validation steps as part of the assay development pro-
cess. Although the number of samples in the PCR cat-
egory was relatively low (535/3,721, 14.4%), our results 
suggest that additional local verification of commercial 
tests may be required before routine use.
Performance of assays within the EIA group was very 
high and consistent overall. This finding is supported 
by previous reports highlighting the suitability of this 
testing method for surveillance programmes [15]. All 
three EIA groups in this analysis, consisting of both 
commercial and in-house assays, had very high confir-
mation rates. However, only a relatively small propor-
tion (578/3,721, 15.5%) of total NHS hospital laboratory 
samples was tested using EIA.
Most NHS hospital laboratories prefer to use rapid 
tests for RV screening, rather than alternative meth-
odologies. Cost and resources are likely to play an 
important part in this decision, since rapid tests are 
relatively inexpensive and easy to use compared with 
EIA and PCR assays that require dedicated equipment 
and trained staff. In contrast, rapid tests for RV are 
designed as point-of-care tests (POCT), which allow 
fast screening for rapid diagnosis, need no specialised 
equipment and can be performed by personnel with 
minimal or no specific laboratory training. In general, 
benefits of a POC testing approach are clear in terms 
of rapid administration of rehydration therapy, isola-
tion or no admission into particular settings (i.e. hos-
pital wards) and reduction in the use of ineffective 
treatments such as antibiotics. However, POCT for RV 
detection have limitations. Our analysis indicates that 
this popular screening method performs poorly, with 
only 66.9% (1,746/2,608) of locally positive samples 
being confirmed as positive by PHE. The overall PPV for 
IC tests in this study is also lower than recent reports 
[15-18]. Similar discrepancies for screening tests have 
been described in the literature. A high proportion of 
false positive results in Australia was reported after an 
unexplained surge in RV cases [19], and an excessive 
number of false positive results by IC tests was also 
reported in Spain [20].
To confirm our findings and support the PHE RV con-
firmation strategy, additional tests were performed 
on positive rapid test samples that failed PHE refer-
ence laboratory confirmatory PCR test detection. The 
rationale for this approach was to use two independent 
assays to confirm VP6 negative samples as true nega-
tives. Results for the NSP3 detection confirmed that 
of the 59 samples available for retesting (with nega-
tive results by VP6 detection test), 57 specimens were 
true negatives, and two samples failed VP6 detec-
tion because of very low RV nucleic acid content. The 
second methodology undertaken was EM, which has 
conventionally been used as a reference method for 
RV detection [21]. The results of both these additional 
assays support the VP6 detection strategy as appropri-
ate for RV confirmation. The limitations of these results 
are the low number of samples available or included 
for testing and the possibility of degradation of sam-
ples due to the time between the initial PHE reference 
laboratory confirmatory PCR tests and later NSP3 PCR 
and EM tests.
Our results suggest that out-of-season false positive 
results are more common for screening tests compared 
with tests performed during the RV season, particu-
larly when rapid tests are used. For the most commonly 
used rapid test, RORT3, the confirmation rate was 
92.7% (114/123) in February 2017, but only 1 in 15 in 
September 2017. A lower PPV can be expected during 
months when RV activity decreases and this will have 
an impact on PHE confirmation rates regardless of the 
screening methodology used by the NHS hospital labo-
ratories. The higher proportion of false positive rapid 
test results when RV activity is lower will also have 
considerable implications for national RV surveillance 
because RV infections have fallen dramatically since 
the introduction of the infant immunisation programme 
[4,5]. The high rates of false positives, especially out-
of-season, will underestimate the true impact and 
effectiveness of the current immunisation programme. 
More importantly, false positive results could have 
important implications for patient diagnosis and sub-
sequent clinical management, and may divert efforts 
to investigate and identify the true cause of illness, 
which could delay the administration of appropriate 
treatment.
There are also cost implications in processing referred 
samples for molecular characterisation if a large pro-
portion of samples are false positive. At the PHE ref-
erence laboratory, characterisation and typing is 
based on analysis and sequencing of RV VP4 and VP7 
gene amplicons, which are both labour-intensive and 
resource-intensive assays.
The strength of this study lies in the availability of a 
single national reference centre for processing RV sam-
ples across England for the purpose of national sur-
veillance. Consistent surveillance has been in place 
since the infant RV immunisation programme began 
more than 5 years ago, and large numbers of samples 
are processed using the same reference laboratory 
protocol every year. A limitation is the different num-
ber of samples analysed within the different catego-
ries, which limits the statistical power for tests with 
relatively small numbers of samples submitted to PHE. 
Our data, however, include results from every sample 
submitted from patients across England over a two-
year period and, therefore, represents the state of RV 
testing at local and national level during 2016 and 
2017. Another limitation is that there may be several 
reasons why local testing may be positive for RV but 
negative with the PHE reference laboratory confirma-
tory PCR test, such as small sample volumes, low RV 
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concentrations or sample degradation. This, however, 
is likely to represent only a small proportion of the 
PHE confirmed negative samples, as supported by 
the results of the two additional detection assays per-
formed on a subset of PHE confirmed positive and con-
firmed negative samples.
Conclusion
A review of the methodologies used for RV initial detec-
tion showed a clear preference for rapid tests among 
NHS hospital laboratories. Rapid tests can be highly 
unreliable if used as the sole diagnostic method; even 
the best performing assays should be considered for 
screening only and should be confirmed using a more 
reliable, confirmatory test. Inconsistencies in confir-
mation rates for IC and other commercial assays, such 
as commercial PCRs, demonstrate the importance of a 
verification process before implementation into clini-
cal settings. Furthermore, this report emphasises the 
need for a confirmatory result to support all screen-
ing tests for diagnosis of RV because the results may 
have implications for both the clinical management of 
patients and national surveillance. A reactive RV detec-
tion result using screening tests should be interpreted 
with caution if used to direct clinical management. 
Surveillance programmes monitoring the effectiveness 
of RV immunisation should be aware of high false posi-
tive rates with commonly used RV screening tests since 
they may underestimate vaccine effectiveness if refer-
ence laboratory confirmation rates are not considered 
alongside.
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